246 related articles for article (PubMed ID: 18713990)
21. Experience-driven development: effector/memory-like alphaE+Foxp3+ regulatory T cells originate from both naive T cells and naturally occurring naive-like regulatory T cells.
Siewert C; Lauer U; Cording S; Bopp T; Schmitt E; Hamann A; Huehn J
J Immunol; 2008 Jan; 180(1):146-55. PubMed ID: 18097014
[TBL] [Abstract][Full Text] [Related]
22. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion.
Gramaglia I; Jember A; Pippig SD; Weinberg AD; Killeen N; Croft M
J Immunol; 2000 Sep; 165(6):3043-50. PubMed ID: 10975814
[TBL] [Abstract][Full Text] [Related]
23. Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells.
So T; Croft M
J Immunol; 2007 Aug; 179(3):1427-30. PubMed ID: 17641007
[TBL] [Abstract][Full Text] [Related]
24. Differential requirements for OX40 signals on generation of effector and central memory CD4+ T cells.
Soroosh P; Ine S; Sugamura K; Ishii N
J Immunol; 2007 Oct; 179(8):5014-23. PubMed ID: 17911586
[TBL] [Abstract][Full Text] [Related]
25. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo.
De Smedt T; Smith J; Baum P; Fanslow W; Butz E; Maliszewski C
J Immunol; 2002 Jan; 168(2):661-70. PubMed ID: 11777959
[TBL] [Abstract][Full Text] [Related]
26. Small-molecule modulators of the OX40-OX40 ligand co-stimulatory protein-protein interaction.
Song Y; Margolles-Clark E; Bayer A; Buchwald P
Br J Pharmacol; 2014 Nov; 171(21):4955-69. PubMed ID: 24930776
[TBL] [Abstract][Full Text] [Related]
27. Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function.
Voo KS; Bover L; Harline ML; Vien LT; Facchinetti V; Arima K; Kwak LW; Liu YJ
J Immunol; 2013 Oct; 191(7):3641-50. PubMed ID: 24014877
[TBL] [Abstract][Full Text] [Related]
28. Effector T cells boost regulatory T cell expansion by IL-2, TNF, OX40, and plasmacytoid dendritic cells depending on the immune context.
Baeyens A; Saadoun D; Billiard F; Rouers A; Grégoire S; Zaragoza B; Grinberg-Bleyer Y; Marodon G; Piaggio E; Salomon BL
J Immunol; 2015 Feb; 194(3):999-1010. PubMed ID: 25548233
[TBL] [Abstract][Full Text] [Related]
29. OX40 controls islet allograft tolerance in CD154 deficient mice by regulating FOXP3+ Tregs.
Chen M; Xiao X; Demirci G; Li XC
Transplantation; 2008 Jun; 85(11):1659-62. PubMed ID: 18551075
[TBL] [Abstract][Full Text] [Related]
30. Tolerogenic dendritic cells induce CD4+CD25hiFoxp3+ regulatory T cell differentiation from CD4+CD25-/loFoxp3- effector T cells.
Huang H; Dawicki W; Zhang X; Town J; Gordon JR
J Immunol; 2010 Nov; 185(9):5003-10. PubMed ID: 20870943
[TBL] [Abstract][Full Text] [Related]
31. Antagonism of airway tolerance by endotoxin/lipopolysaccharide through promoting OX40L and suppressing antigen-specific Foxp3+ T regulatory cells.
Duan W; So T; Croft M
J Immunol; 2008 Dec; 181(12):8650-9. PubMed ID: 19050285
[TBL] [Abstract][Full Text] [Related]
32. CD4(+)CD62L(+) central memory T cells can be converted to Foxp3(+) T cells.
Zhang X; Chang Li X; Xiao X; Sun R; Tian Z; Wei H
PLoS One; 2013; 8(10):e77322. PubMed ID: 24155942
[TBL] [Abstract][Full Text] [Related]
33. CD4 blockade directly inhibits mouse and human CD4(+) T cell functions independent of Foxp3(+) Tregs.
Mayer CT; Huntenburg J; Nandan A; Schmitt E; Czeloth N; Sparwasser T
J Autoimmun; 2013 Dec; 47():73-82. PubMed ID: 24055067
[TBL] [Abstract][Full Text] [Related]
34. OX40 and OX40L Interaction in Cancer.
Lu X
Curr Med Chem; 2021; 28(28):5659-5673. PubMed ID: 33372866
[TBL] [Abstract][Full Text] [Related]
35. Costimulation through OX40 is crucial for induction of an alloreactive human T-cell response.
Ukyo N; Hori T; Yanagita S; Ishikawa T; Uchiyama T
Immunology; 2003 Jun; 109(2):226-31. PubMed ID: 12757617
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of CD4(+) T cell response and survival via coexpressed OX40/OX40L in Graves' disease.
Wang Q; Shi BM; Xie F; Fu ZY; Chen YJ; An JN; Ma Y; Liu CP; Zhang XK; Zhang XG
Mol Cell Endocrinol; 2016 Jul; 430():115-24. PubMed ID: 27107937
[TBL] [Abstract][Full Text] [Related]
37. Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.
Oberst MD; Augé C; Morris C; Kentner S; Mulgrew K; McGlinchey K; Hair J; Hanabuchi S; Du Q; Damschroder M; Feng H; Eck S; Buss N; de Haan L; Pierce AJ; Park H; Sylwester A; Axthelm MK; Picker L; Morris NP; Weinberg A; Hammond SA
Mol Cancer Ther; 2018 May; 17(5):1024-1038. PubMed ID: 29545330
[TBL] [Abstract][Full Text] [Related]
38. OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity.
Soroosh P; Ine S; Sugamura K; Ishii N
J Immunol; 2006 May; 176(10):5975-87. PubMed ID: 16670306
[TBL] [Abstract][Full Text] [Related]
39. Role of Thalidomide on the Expression of OX40, 4-1BB, and GITR in T Cell Subsets.
Kim BS; Kim JY; Kim EJ; Lee JG; Joo DJ; Huh KH; Kim MS; Kim YS
Transplant Proc; 2016 May; 48(4):1270-4. PubMed ID: 27320601
[TBL] [Abstract][Full Text] [Related]
40. Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases.
Murata K; Nose M; Ndhlovu LC; Sato T; Sugamura K; Ishii N
J Immunol; 2002 Oct; 169(8):4628-36. PubMed ID: 12370402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
